Механизмы развития легочной гипертензии у детей с бронхолегочной дисплазией

Цель обзора: определить механизмы развития легочной гипертензии у детей, страдающих бронхолегочной дисплазией.

Основные положения. Патогенез бронхолегочной дисплазии в настоящее время остается до конца не изученным. Важную роль играют изменения в передаче внутриклеточных сигналов, влияющих на регуляцию ангиогенеза. Гипоксия, гипероксия и воздействие искусственной вентиляции легких приводят к оксидативному и воспалительному стрессу, вызывая повреждение в альвеолах легких и сосудистой сети с развитием легочной гипертензии. Необходимо понимание взаимодействия факторов роста, факторов транскрипции и воспалительных процессов, регулирующих нормальное развитие паренхимы и микрососудистого русла легких для разработки превентивных подходов.

Заключение. Дальнейшее изучение роли значимых биомаркеров формирования бронхолегочной дисплазии может помочь в ранней диагностике и профилактике развития этого заболевания, а также такого грозного его осложнения, как легочная гипертензия.

1. Sahni M., Bhandari V. Patho-mechanisms of the origins of bronchopulmonary dysplasia. Mol. Cell Pediatr. 2021; 8: 21. DOI: 10.1186/s40348-021-00129-5

2. Hansmann G., Sallmon H., Roehr C.C., Kourembanas S. et al. European Pediatric Pulmonary Vascular Disease Network (EPPVDN). Pulmonary hypertension in bronchopulmonary dysplasia. Pediatr. Res. 2021; 89(3): 446–55. DOI: 10.1038/s41390-020-0993-4

3. Mathew R. Signaling pathways involved in the development of bronchopulmonary dysplasia and pulmonary hypertension. Children (Basel). 2020; 7(8): 100. DOI: 10.3390/children7080100

4. Chen S., Rong M., Platteau A., Hehre D. et al. CTGF disrupts alveolarization and induces pulmonary hypertension in neonatal mice: implication in the pathogenesis of severe bronchopulmonary dysplasia. Am. J. Physiol. Lung Cell Mol. Physiol. 2011; 300(3): L330–40. DOI: 10.1152/ajplung.00270.2010

5. Stark A., Dammann C., Nielsen H.C., Volpe M.V. A pathogenic relationship of bronchopulmonary dysplasia and retinopathy of prematurity? A review of angiogenic mediators in both diseases. Front. Pediatr. 2018; 6: 125. DOI: 10.3389/fped.2018.00125

6. Hilgendorff A., Reiss I., Ehrhardt H., Eickelberg O. et al. Chronic lung disease in the preterm infant. Lessons learned from animal models. Am. J. Respir. Cell Mol. Biol. 2014; 50(2): 233–45. DOI: 10.1165/rcmb.2013-0014TR

7. Salaets T., Gie A., Tack B., Deprest J. et al. Modelling bronchopulmonary dysplasia in animals: arguments for the preterm rabbit model. Curr. Pharm. Des. 2017; 23(38): 5887–901. DOI: 10.2174/1381612823666170926123550

8. Mandell E.W., Abman S.H. Fetal vascular origins of bronchopulmonary dysplasia. J Pediatr. 2017; 185: 7–10.e1. DOI: 10.1016/j.jpeds.2017.03.024

9. Morrow L.A., Wagner B.D., Ingram D.A., Poindexter B.B. et al. Antenatal determinants of bronchopulmonary dysplasia and late respiratory disease in preterm infants. Am. J. Respir. Crit. Care Med. 2017; 196(3): 364–74. DOI: 10.1164/rccm.201612-2414OC

10. Mestan K.K., Gotteiner N., Prota N., Grobman W. et al. Cord blood biomarkers of placental maternal vascular underperfusion predict bronchopulmonary dysplasia-associated pulmonary hypertension. J. Pediatr. 2017; 185: 33–41. DOI: 10.1016/j.jpeds.2017.01.015

11. Wallace B., Peisl A., Seedorf G., Nowlin T. et al. Anti-sFlt-1 therapy preserves lung alveolar and vascular growth in antenatal models of bronchopulmonary dysplasia. Am. J. Respir. Crit. Care Med. 2018; 197(6): 776–87. DOI: 10.1164/rccm.201707-1371OC

12. Villamor-Martinez E., Álvarez-Fuente M., Ghazi A.M.T., Degraeuwe P. Association of chorioamnionitis with bronchopulmonary dysplasia among preterm infants: a systematic review, meta-analysis, and metaregression. JAMA Netw. Open. 2019; 2(11): e1914611. DOI: 10.1001/jamanetworkopen.2019.14611

13. Watterberg K.L., Demers L.M., Scott S.M., Murphy S. Chorioamnionitis and early lung inflammation in infants in whom bronchopulmonary dysplasia develops. Pediatrics. 1996; 97(2): 210–5.

14. Willems M.G.M., Kemp M.W., Fast L.A., Wagemaker N.M.M. et al. Pulmonary vascular changes in extremely preterm sheep after intra amniotic exposure to Ureaplasma parvum and lipopolysaccharide. PLoS One. 2017; 12(6): e0180114. DOI: 10.1371/journal.pone.0180114

15. Been J.V., Debeer A., van Iwaarden J.F., Kloosterboer N. et al. Early alterations of growth factor patterns in bronchoalveolar lavage fluid from preterm infants developing bronchopulmonary dysplasia. Pediatr. Res. 2010; 67(1): 83–9. DOI: 10.1203/PDR.0b013e3181c13276

16. Dumas de la Roque E., Smeralda G., Quignard J.F., Freund-Michel V. et al. Altered vasoreactivity in neonatal rats with pulmonary hypertension associated with bronchopulmonary dysplasia: Implication of both eNOS phosphorylation and calcium signaling. PLoS One. 2017; 12(2): e0173044. DOI: 10.1371/journal.pone.0173044

17. Melincovici C.S., Boşca A.B., Şuşman S., Mărginean M. et al. Vascular endothelial growth factor (VEGF) — key factor in normal and patholo gical angiogenesis. Rom. J. Morphol. Embryol. 2018; 59(2): 455–67.

18. Syed M., Das P., Pawar A., Aghai Z.H. et al. Hyperoxia causes miR 34a-mediated injury via angiopoietin-1 in neonatal lungs. Nat. Commun. 2017; 8(1): 1173. DOI: 10.1038/s41467-017-01349-y

19. Kim D.-H., Kim H.-S. Serial changes of serum endostatin and angiopoietin-1 levels in preterm infants with severe bronchopulmonary dysplasia and subsequent pulmonary artery hypertension. Neonatology. 2014; 106(1): 55–61. DOI: 10.1159/000358374

20. Salimi U., Menden H.L., Mabry S.M., Xia S. et al. Angiopoietin-1 protects against endotoxin-induced neonatal lung injury and alveolar simplification in mice. Pediatr. Res. 2022; 91(6): 1405–15. DOI: 10.1038/s41390-021-01544-0

21. Shafiee A., Penn J.S., Krutzsch H.C., Inman J.K. et al. Inhibition of retinal angiogenesis by peptides derived from thrombospondin-1. Invest. Ophthalmol. Vis. Sci. 2000; 41(8): 2378–88. 22. Oak P., Hilgendorff A. The BPD trio? Interaction of dysregulated PDGF, VEGF, and TGF signaling in neonatal chronic lung disease. Mol. Cell Pediatr. 2017; 4(1): 11. DOI: 10.1186/s40348-017-0076-8

22. De Paepe M.E., Mao Q., Powell J., Rubin S.E. et al. Growth of pulmonary microvasculature in ventilated preterm infants. Am. J. Respir. Crit. Care Med. 2006; 173(2): 204–11. DOI: 10.1164/rccm.200506-927OC

23. Rebetz J., Semple J.W., Kapur R. The pathogenic involvement of neutrophils in acute respiratory distress syndrome and transfusion related acute lung injury. Transfus. Med. Hemother. 2018; 45(5): 290–8. DOI: 10.1159/000492950

24. Collaco J.M., McGrath-Morrow S.A., Griffiths M., Chavez-Valdez R. et al. Perinatal inflammatory biomarkers and respiratory disease in preterm infants. J. Pediatr. 2022; 246: 34–9.e3. DOI: 10.1016/j.jpeds.2022.04.028

25. El Agha E., Moiseenko A., Kheirollahi V., De Langhe S. e al. Two-way conversion between lipogenic and myogenic fibroblastic phenotypes marks the progression and resolution of lung fibrosis. Cell Stem. Cell. 2017; 20(2): 261–73.e3. DOI: 10.1016/j.stem.2016.10.004

26. Chao C.M., Moiseenko A., Kosanovic D., Rivetti, S. et al. Impact of Fgf10 deficiency on pulmonary vasculature formation in a mouse model of bronchopulmonary dysplasia. Hum. Mol. Genet. 2019; 28(9): 1429 44. DOI: 10.1093/hmg/ddy439

27. Chao C.M., Yahya F., Moiseenko A., Tiozzo C. et al. Fgf10 deficiency is causative for lethality in a mouse model of bronchopulmonary dysplasia. J. Pathol. 2017; 241(1): 91–103. DOI: 10.1002/path.4834

28. Бондарь В.А., Давыдова И.В., Басаргина М.А., Фисенко А.П. и др. Роль генетических предикторов в доклинической диагностике бронхолегочной дисплазии Кремлевская медицина. 2022; 1: 5–9. [Bondar V.A., Davydova I.V., Basargina M.A., Fisenco A.P. et al. The role of genetic predictors in preclinical diagnostics of bronchopulmonary dysplasia. Kremlin Medicine Journal. 2022; 1: 5–9. (in Russian)]. DOI: 10.26269/m7zs-qa3

29. Ren Y., Lyu Y., Mereness J.A., Wang S. et al. Rare pulmonary connective tissue type mast cells regulate lung endothelial cell angiogenesis. Am. J. Pathol. 2020; 190(8): 1763–73. DOI: 10.1016/j.ajpath.2020.04.017

30. Winter N.A., Gibson P.G., McDonald V.M., Fricker M. Sputum gene expression reveals dysregulation of mast cells and basophils in eosinophilic COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2021; 16: 2165–79. DOI: 10.2147/COPD.S305380

31. Ramazani Y., Knops N., Elmonem M.A., Nguyen T.Q. et al. Connective tissue growth factor (CTGF) from basics to clinics. Matrix Biol. 2018; 68–69: 44–66. DOI: 10.1016/j.matbio.2018.03.007

32. Wang X., Cui H., Wu S. CTGF: a potential therapeutic target for bronchopulmonary dysplasia. Eur. J. Pharmacol. 2019; 860: 172588. DOI: 10.1016/j.ejphar.2019.172588

33. Wu S., Platteau A., Chen S., McNamara G. et al. Conditional overexpression of connective tissue growth factor disrupts postnatal lung development. Am. J. Respir. Cell Mol. Biol. 2010; 42(5): 552–63. DOI: 10.1165/rcmb.2009-0068OC

34. McDonald P.C., Fielding A.B., Dedhar S. Integrin-linked kinase — essential roles in physiology and cancer biology. J. Cell Sci. 2008; 121(pt19): 3121–32. DOI: 10.1242/jcs.017996

35. Varghese S., Braggio D.A., Gillespie J., Toland A.E. et al. TGF-β and CTGF are mitogenic output mediators of wnt/β-catenin signaling in desmoid fibromatosis. Appl. Immunohistochem. Mol. Morphol. 2017; 25(8): 559–65. DOI: 10.1097/PAI.0000000000000340

36. Kim H.T., Panza P., Kikhi K., Nakamichi Y. et al. WNT/RYK signaling functions as an antiinflammatory modulator in the lung mesen chyme. Proc. Natl. Acad. Sci. USA. 2022; 119(24): e2201707119. DOI: 10.1073/pnas.2201707119

37. Alapati D., Rong M., Chen S., Hehre D. et al. Connective tissue growth factor antibody therapy attenuates hyperoxia-induced lung injury in neonatal rats. Am. J. Respir. Cell Mol. Biol. 2011; 45(6): 1169–77. DOI: 10.1165/rcmb.2011-0023OC

38. Mathew R. Signaling pathways involved in the development of bronchopulmonary dysplasia and pulmonary hypertension. Children (Basel). 2020; 7(8): 100. DOI: 10.3390/children7080100

39. Yanagihara T., Tsubouchi K., Gholiof M., Chong S.G. et al. Connective tissue growth factor contributes to TGF-β1-induced lung fibrosis. Am. J. Respir. Cell Mol. Biol. 2022; 66(3): 260–70. DOI: 10.1165/rcmb.2020-0504OC

40. Inoki I., Shiomi T., Hashimoto G., Enomoto H. et al. Connective tissue growth factor binds vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis. FASEB J. 2002; 16(2): 219–21. DOI: 10.1096/fj.01-0332fje

41. Pi L., Fu C., Lu Y., Zhou J. et al. Vascular endothelial cell-specific connective tissue growth factor (CTGF) is necessary for development of chronic hypoxia-induced pulmonary hypertension. Front. Physiol. 2018; 9: 138. DOI: 10.3389/fphys.2018.00138

42. Speer C.P. Inflammation and bronchopulmonary dysplasia: a continuing story. Semin. Fetal Neonatal Med. 2006; 11(5): 354–62. DOI: 10.1016/j.siny.2006.03.004

43. Kuiper E.J., Roestenberg P., Ehlken C., Lambert V. et al. Angiogenesis is not impaired in connective tissue growth factor (CTGF) knock out mice. J. Histochem. Cytochem. 2007; 55(11): 1139–47. DOI: 10.1369/jhc.7A7258.2007

44. Grover T.R., Parker T.A., Zenge J.P., Markham N.E. et al. Intrauterine hypertension decreases lung VEGF expression and VEGF inhibition causes pulmonary hypertension in the ovine fetus. Am. J. Physiol. Lung Cell Mol. Physiol. 2003; 284(3): L508–17. DOI: 10.1152/ajplung.00135.2002